Document Detail

Clinical germline genetic testing for melanoma.
MedLine Citation:
PMID:  15120668     Owner:  NLM     Status:  MEDLINE    
Clinical genetic testing for mutations in CDKN2A (cyclin-dependent kinase inhibitor 2A), a melanoma susceptibility gene, is now available. The International Melanoma Genetics Consortium advocates that genetic testing for CDKN2A should be done only as part of a research protocol. Experience with genetic testing for other cancer-susceptibility genes indicates that CDKN2A testing has enormous potential for the prevention and detection of a deadly disease. However, clinicians need to understand the benefits and shortcomings of clinical CDKN2A testing so that it can be used advantageously. Here, we examine whether CDKN2A meets the recommendations of the American Society of Clinical Oncology (ASCO) for cancer-susceptibility genetic testing. Although genetic testing for hereditary melanoma should, whenever possible, occur within research protocols, it might be successfully done outside of research protocols if attention is paid to selection, education, and counselling needs of patients; valid test interpretation; and the changing of medical management in appropriate individuals.
Christopher B Hansen; Lisa M Wadge; Katrina Lowstuter; Kenneth Boucher; Sancy A Leachman
Related Documents :
8733168 - Porphyria: a new perspective.
20179748 - Consensus and controversies in best practices for molecular genetic testing of spinocer...
12582018 - Intention to pursue genetic testing for breast cancer among women due for screening mam...
11374708 - Motivations and concerns of patients with access to genetic testing for hereditary panc...
24290138 - Changes in the interfacial shear resistance of disc annulus fibrosus from genipin cross...
12184218 - A two-probe laser doppler flowmetry assessment as an exclusive diagnostic device in a l...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.; Review    
Journal Detail:
Title:  The Lancet. Oncology     Volume:  5     ISSN:  1470-2045     ISO Abbreviation:  Lancet Oncol.     Publication Date:  2004 May 
Date Detail:
Created Date:  2004-05-03     Completed Date:  2004-05-27     Revised Date:  2014-08-18    
Medline Journal Info:
Nlm Unique ID:  100957246     Medline TA:  Lancet Oncol     Country:  England    
Other Details:
Languages:  eng     Pagination:  314-9     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Cyclin-Dependent Kinase Inhibitor p16 / genetics*
Genetic Predisposition to Disease*
Genetic Testing*
Melanoma / genetics*
Skin Neoplasms / genetics*
Reg. No./Substance:
0/Cyclin-Dependent Kinase Inhibitor p16

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Environmental, genetic, and molecular features of prostate cancer.
Next Document:  To sleep, perchance to gain creative insight?